Boehringer and Re-Vana partner on long-acting ophthalmic therapies
Boehringer Ingelheim and Re-Vana Therapeutics have announced a strategic collaboration and license agreement to develop first-in-class extended-release therapies for eye diseases.
Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients.
Re-Vana’s drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections.
“We’re looking forward to team up with Re-Vana to push the boundaries of what’s possible in eye health,” said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. “Together, we want to tackle the limits of today’s treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.”
Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities.
The companies will jointly oversee Re-Vana’s feasibility and development activities for the extended-release programmes, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialisation of the products.
The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales.
“The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,” said Michael O’Rourke, Re-Vana Chief Executive Officer. “By combining our extended-release platform with Boehringer Ingelheim’s world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.”
Diana Turner, Senior Digital Content Editor, DDW
